Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a clinical-stage biotechnology company focused on therapies for immune-mediated and metabolic diseases, with a particular emphasis on ophthalmology and rare retinal conditions. News about Aldeyra often centers on the progress of its RASP (reactive aldehyde species) modulator platform and its late-stage product candidates reproxalap and ADX-2191.
Investors following ALDX news can expect regular updates on regulatory milestones, such as the U.S. Food and Drug Administration’s review of the New Drug Application for topical ocular reproxalap in dry eye disease, extensions of Prescription Drug User Fee Act (PDUFA) target action dates, and feedback on proposed labeling. Aldeyra also reports on orphan drug and fast track designations from the FDA and the European Medicines Agency for ADX-2191 in primary vitreoretinal lymphoma, retinitis pigmentosa, and related inherited retinal dystrophies.
The company’s news flow includes clinical trial readouts and pipeline updates, such as Phase 2 data for ADX-629 in alcohol-associated hepatitis, preclinical results for ADX-248 in models of central nervous system diseases associated with inflammation, and decisions to prioritize next-generation RASP modulators ADX-248 and ADX-246. Aldeyra also issues releases about Special Protocol Assessment agreements, manufacturing inspections and outcomes, and participation in healthcare and ophthalmology conferences and research and development webcasts.
This ALDX news page aggregates these company communications so readers can track developments in Aldeyra’s RASP platform, ophthalmic programs, and broader immune-mediated disease pipeline over time. For investors and observers, the news stream provides context on clinical progress, regulatory interactions, and strategic pipeline decisions that shape the company’s future prospects.
Aldeyra Therapeutics (NASDAQ: ALDX) has submitted a New Drug Application (NDA) to the FDA for its investigational drug reproxalap, targeting dry eye disease symptoms. This NDA is backed by data from five clinical trials, indicating efficacy and safety in over 2,000 patients, with minimal adverse effects noted. Reproxalap aims to be the first marketed RASP modulator for dry eye disease, a condition affecting over 39 million adults in the U.S. Additionally, reproxalap is in late-stage trials for allergic conjunctivitis, with results expected in 2023.
Aldeyra Therapeutics (ALDX) announced key developments and financial results for Q3 2022, with cash reserves exceeding $185 million. The NDA for Reproxalap for dry eye disease is on track for submission in Q4 2022, following an FDA pre-NDA meeting. The company also reported favorable results for ADX-2191 in clinical trials related to proliferative vitreoretinopathy, and plans upcoming NDA submissions for lymphoma. The net loss for the quarter was $14.6 million, an improvement from $15.8 million the previous year, with reduced R&D expenses.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will hold a conference call at 8:00 a.m. ET on November 10, 2022, to discuss financial results for the quarter ended September 30, 2022, and provide corporate highlights. Domestic callers can dial (844) 200-6205, and international callers can reach (929) 526-1599 with access code 048610. A live audio webcast will be available on the company's website and archived for 90 days.
Aldeyra Therapeutics (NASDAQ: ALDX) announced an upcoming oral presentation of clinical data from the Phase 3 INVIGORATE trial for reproxalap, designed to treat allergic conjunctivitis. Scheduled for October 26, 2022, at the American Academy of Optometry Annual Meeting in San Diego, the presentation will highlight clinically significant reductions in ocular itching and redness compared to a vehicle. Reproxalap is a first-in-class drug targeting reactive aldehyde species linked to ocular inflammation and is also in late-stage trials for dry eye disease.
Aldeyra Therapeutics (ALDX) announced that ADX-2191 achieved its primary endpoint in Part 1 of the Phase 3 GUARD Trial, demonstrating statistical superiority in preventing retinal detachment associated with proliferative vitreoretinopathy (PVR) (P=0.024). The trial involved 68 patients receiving ADX-2191 compared to 38 patients receiving routine surgical care. Notably, ADX-2191 was well tolerated with no significant safety concerns. The company plans discussions with the FDA regarding the completion of clinical development in the first half of 2023, aiming to address this rare disease's unmet medical needs.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will host a webcast on October 6, 2022, at 8:00 a.m. ET to report top-line results from Part 1 of the Phase 3 GUARD Trial for ADX-2191, an innovative treatment for proliferative vitreoretinopathy (PVR), a vision-threatening condition without available therapies. The conference call can be accessed via a dial-in number or through a live audio webcast on the company’s website, with archived access for 90 days post-event.
Aldeyra Therapeutics (NASDAQ: ALDX) announced plans to submit a New Drug Application (NDA) for its investigational drug reproxalap for dry eye disease in Q4 2022, following a productive pre-NDA meeting with the FDA. The NDA will be supported by data from five completed clinical trials, showcasing rapid symptom relief and improved objective signs of dry eye disease. Additionally, upcoming milestones include a pre-NDA meeting for ADX-2191 and results from various clinical trials expected in late 2022 and early 2023.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that CEO Todd C. Brady will participate in key investor conferences in September 2022. The events include Citi's 17th Annual BioPharma Conference on September 7 in Boston, and H.C. Wainwright's 24th Annual Global Investment Conference on September 14 in New York. Dr. Brady's presentation at the latter is set for 10:00 a.m. ET and can be accessed via Aldeyra's website. Aldeyra focuses on innovative treatments for immune-mediated diseases, with products like reproxalap and ADX-629 in various clinical stages.
Aldeyra Therapeutics (Nasdaq: ALDX) reported significant progress in Q2 2022, with cash reserves of $196.7 million expected to support operations into 2023. Key upcoming milestones include pre-NDA meetings with the FDA for reproxalap, aimed at treating dry eye disease, and ADX-2191 for primary vitreoretinal lymphoma. Positive results from clinical trials of reproxalap indicated statistical superiority in reducing ocular discomfort. However, the company reported a net loss of $17.8 million for the quarter, an increase from the prior year, primarily due to rising R&D expenses.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will host a conference call on August 5, 2022, at 8:00 a.m. ET to discuss its financial results for Q2 2022, which ended June 30, 2022, along with recent corporate highlights. Domestic callers can dial (844) 200-6205 or (929) 526-1599 for international calls, using access code 908644. A live audio webcast will also be available on Aldeyra's website and will remain archived for 90 days. Aldeyra focuses on innovative therapies for immune-mediated diseases, with key products in development addressing various conditions.